Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ontorpacept - Trillium Therapeutics

Next Previous
Drug Profile

Ontorpacept - Trillium Therapeutics

Alternative Names: CD47 antigen/SIRPalpha protein modulator - Trillium Therapeutics; SIRPaFc; SIRPalphaFc; TTI-621

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Hospital for Sick Children; University Health Network
  • Developer Trillium Therapeutics Inc
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Leiomyosarcoma
  • Phase I Haematological malignancies; Multiple myeloma; Small cell lung cancer; Solid tumours
  • No development reported Mycosis fungoides; Sezary syndrome

Most Recent Events

  • 07 Dec 2023 Pfizer terminates a phase I/II trial in Leiomyosarcoma ( Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV) due to administrative reasons(NCT04996004)
  • 16 Jun 2023 Ontorpacept is still in phase I trials for Haematological malignancies (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) (IV) in USA, Canada (NCT02663518)
  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Leiomyosarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top